在正在进行的癌症药物试验中,Adagene于2025年11月15日升级为"强购". Adagene upgraded to "strong-buy" on Nov. 15, 2025, amid ongoing cancer drug trials.

Adagene(ADG)于2025年11月15日从Lifesci Capital获得“强购”评级升级, Adagene (ADAG) received a "strong-buy" rating upgrade from Lifesci Capital on November 15, 2025, joining other firms that have recently upgraded the stock. 临床阶段生物技术为癌症开发单克隆抗体疗法,在固体肿瘤和淋巴瘤试验中有若干候选者。 The clinical-stage biotech, developing monoclonal antibody therapies for cancer, has several candidates in trials for solid tumors and lymphomas. 该股收盘价为1.83美元，上涨0.03美元，成交量低于平均水平。 The stock closed at $1.83, up $0.03, with below-average volume. 分析师维持协商一致的“中价购买”评级和平均7.00美元12个月价格指标。 Analysts maintain a consensus "moderate buy" rating and a $7.00 average 12-month price target. 体制所有权占9.51%。 Institutional ownership is 9.51%.